6.24
+1.63%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PolyPid
Its shares trade under the ticker PYPD. It has been listed since 26 June 2020.
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 26 Jun 2020
- Employees
- 59
- Website
- polypid.com ↗
- Head office
- 18 HASIVIM STREET, PETACH TIKVA, L3, 4959376
- Incorporated in
- L3
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Mr. Jacob HarelIndependent Chairman of the Board
- Ms. Dikla AkselbradChief Executive Officer, Director, since 2014$848,247
- Dr. Shaul MukhtarChief Operating Officer, Executive Vice President
- Ms. Dalit HazanSenior Vice President - Research and Development and Regulatory Affairs$479,320
- Dr. Noam EmanuelChief Scientific Officer, since 2008$1.1m
- Mr. Ori WarshavskyChief Operating Officer - US$521,246
- Dr. Yechezkel BarenholzIndependent Director
- Mr. Nir DrorIndependent Director
- Mr. Chaim HurvitzIndependent Director
- Dr. Itzhak KrinskyIndependent Director
- Mrs. Anat SegalIndependent Director
- Dr. Robert SteinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PolyPid Ltd has several strengths that contribute to its competitive advantage:
- PolyPid has developed a novel drug delivery system that enables the controlled release of antibiotics directly at the site of infection, improving efficacy and reducing potential side effects.
- The company has a robust portfolio of patents protecting its technology and product candidates, providing a barrier to entry for potential competitors.
- PolyPid is led by a skilled management team with extensive expertise in the pharmaceutical and medical device industry, ensuring effective strategic decision-making and execution.
Weaknesses
- Despite its strengths, PolyPid Ltd also faces some weaknesses that need to be addressed:
- At the moment, PolyPid has a relatively small pipeline of product candidates, which may limit its revenue potential and growth opportunities.
- Developing and gaining regulatory approval for new medical devices can be a complex and time-consuming process, posing potential challenges to PolyPid's product development timeline and market entry.
- PolyPid relies on strategic collaborations and partnerships with larger pharmaceutical companies to advance its products, making it vulnerable to the decisions and priorities of its partners.
Opportunities
- PolyPid Ltd can take advantage of several opportunities in the market:
- The increasing prevalence of antibiotic-resistant infections creates a significant market opportunity for PolyPid's targeted drug delivery system, providing solutions for improved patient outcomes.
- PolyPid can explore expanding its drug delivery technology beyond antibiotics and into other therapeutic areas, such as antifungals or chemotherapy drugs, diversifying its product portfolio.
- Forming strategic partnerships and licensing agreements with international pharmaceutical companies can facilitate global market expansion and enhance PolyPid's reach.
Threats
- PolyPid Ltd must also be aware of potential threats in the market:
- The pharmaceutical and medical device industry is highly competitive, with established companies and emerging startups developing innovative drug delivery technologies, posing a threat to PolyPid's market share.
- Stringent regulatory requirements and potential delays in reimbursement decisions can impede market adoption and limit the widespread use of PolyPid's products.
- Economic downturns, changes in healthcare policies, and pricing pressures can impact the healthcare industry, potentially affecting PolyPid's market potential and revenue growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.